Work

Supplementary Data from Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT

Year: 2023
Type: supplementary-materials
Abstract: Supplementary Data from Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4361828056
Cites:
Cited by:
Related to: 10